OnKure Therapeutics (OKUR) versus Its Peers Head to Head Comparison

OnKure Therapeutics (NASDAQ:OKUR) is one of 1,049 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its competitors? We will compare OnKure Therapeutics to similar businesses based on the strength of its earnings, dividends, institutional ownership, risk, valuation, profitability and analyst recommendations.

Profitability

This table compares OnKure Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-51.17%	-47.11%
OnKure Therapeutics Competitors	-3,610.16%	-274.38%	-39.07%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for OnKure Therapeutics and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	0	0	2	1	3.33
OnKure Therapeutics Competitors	7622	20908	48546	1193	2.55

OnKure Therapeutics presently has a consensus target price of $37.50, suggesting a potential upside of 142.25%. As a group, “Pharmaceutical preparations” companies have a potential upside of 71.63%. Given OnKure Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe OnKure Therapeutics is more favorable than its competitors.

Institutional and Insider Ownership

91.0% of OnKure Therapeutics shares are held by institutional investors. Comparatively, 44.3% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 17.9% of OnKure Therapeutics shares are held by company insiders. Comparatively, 13.8% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares OnKure Therapeutics and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
OnKure Therapeutics	N/A	-$77.39 million	-1.27
OnKure Therapeutics Competitors	$1.72 billion	$154.84 million	-5.58

OnKure Therapeutics’ competitors have higher revenue and earnings than OnKure Therapeutics. OnKure Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

OnKure Therapeutics has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500. Comparatively, OnKure Therapeutics’ competitors have a beta of 1.00, suggesting that their average stock price is 0% more volatile than the S&P 500.

Summary

OnKure Therapeutics beats its competitors on 9 of the 13 factors compared.

About OnKure Therapeutics

Reneo Pharmaceuticals Inc.is a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Inc.is based in SAN DIEGO.